Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of “Hold” by Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been assigned an average recommendation of “Hold” from the three brokerages that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.00.

Several equities research analysts have commented on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday. They set a “neutral” rating and a $20.00 target price on the stock. Leerink Partners started coverage on Beta Bionics in a research note on Monday. They set an “outperform” rating and a $28.00 price objective on the stock. Robert W. Baird initiated coverage on shares of Beta Bionics in a research report on Thursday. They issued a “neutral” rating and a $20.00 price objective for the company. Stifel Nicolaus initiated coverage on Beta Bionics in a research report on Monday. They set a “buy” rating and a $25.00 target price on the stock. Finally, Piper Sandler started coverage on shares of Beta Bionics in a research report on Monday. They issued an “overweight” rating and a $26.00 target price on the stock.

Insider Activity

In related news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the acquisition, the insider now owns 3,901,599 shares in the company, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mike Mensinger acquired 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now owns 59,019 shares of the company’s stock, valued at $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Trading Down 1.4 %

BBNX opened at $20.57 on Monday. Beta Bionics has a 52 week low of $20.57 and a 52 week high of $24.50.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.